長江生命科技(00775.HK)2021年純利增長30%至1.63億港元 末期息0.01港元
格隆匯3月15日丨長江生命科技(00775.HK)發佈公吿,截至2021年12月31日止年度,公司收入54億港元,同比增長9.3%;公司股東應占溢利1.63億港元,同比增長30%;每股盈利1.69仙,末期股息每股港幣0.01元。
保健產品業務於年內復甦理想,收入比2020年上升11%。在2019冠狀病毒疫情持續威脅下,消費者的保健意識與日俱增,帶動市場對維他命及保健品的整體需求。儘管供應鏈中斷及勞工短缺問題持續,導致成本上漲,但有效的定價策略及優化措施均有助減輕相關影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.